Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Other: continuous insulin therapy
- Registration Number
- NCT00993720
- Lead Sponsor
- Hvidovre University Hospital
- Brief Summary
The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- age 18-50y,
- BMI 18-27,
- caucasian origin,
- type 1 diabetes diagnosed between age 5 and age 40,
- no known diabetes complications or cardiovascular diseases,
- no medication known to influence glucose homeostasis,
- no pregnancy
Exclusion Criteria
- diabetes complications,
- autonomous nerve dysfunction,
- anaemia,
- HbA1c < 8.5% at screening,
- estimated by the investigator to be incapable of completing the trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description type 1 DM with betacell function: Liraglutide Liraglutide - type 1 DM without betacell function: Liraglutide Liraglutide - type 1 DM without betacell function: Insulin continuous insulin therapy -
- Primary Outcome Measures
Name Time Method insulin-dose 4 weeks
- Secondary Outcome Measures
Name Time Method 24-hours glucose profiles with and without treatment of Victoza three days risk of hypoglycemia during physical activity with and without Victoza one day gastric emptying rate during hypoglycemia with and without Victoza one day weight change from baseline, change in fructosamine from baseline four weeks
Trial Locations
- Locations (1)
Hvidovre University Hospital
🇩🇰Hvidovre, Denmark